Immunology Market Trends: Expansion, Durability, Safety and Smarter Discovery Shape the Next Competitive Advancement in Immunology
Coverage: August 18 – September 22, 2026
Introduction
Several immunology market trends stood out during this reporting period. Established mechanisms expanded into new diseases, while more complex therapeutic modalities encountered emerging safety constraints.
Late-stage and longer-term data strengthened the case for extending existing biology across epithelial, gastrointestinal, rheumatologic and neuroimmune diseases. At the same time, safety-related pauses in autoimmune CAR-T programs showed that therapeutic ambition can quickly encounter development limits when modality risk increases. In parallel, new AI partnerships suggest that competition is moving upstream, with proprietary data and discovery platforms becoming a more deliberate part of immunology R&D strategy.
Companies covered: AstraZeneca, Roche, Teva, Bristol Myers Squibb, Owkin, Boehringer Ingelheim, AbbVie and Iambic Therapeutics
Executive Summary
- Mechanism expansion gained momentum across immunology. Positive Phase III data for tezepelumab in eosinophilic esophagitis, regulatory progress for satralizumab in MOGAD and Phase IIa results for TEV ’408 in celiac disease reinforced the value of therapies that can address multiple diseases through a shared biological pathway.
- Autoimmune CAR-T faced an important safety test. Trial pauses involving rap-cel and zola-cel highlighted the need to understand how manufacturing, cellular expansion, patient selection and toxicity management influence the risk-benefit profile of cell therapy outside oncology.
- Durability and relapse prevention are becoming more important competitive evidence. Two-year deucravacitinib data in psoriatic arthritis, sustained tezepelumab efficacy in EoE and satralizumab relapse-prevention data in MOGAD show how longer-term disease control can strengthen differentiation beyond initial efficacy.
- AI is moving closer to core immunology discovery infrastructure. Partnerships involving multimodal patient data, AI-enabled hypothesis generation and molecular design indicate that competitive advantage may increasingly depend on how effectively companies integrate computational capabilities into target selection and drug development.
Watch the video summary
Strategic Perspective on the latest Immunology Market Trends
Multi-Indication Immunology Strategies Raise the Value of Mechanism Portability
Several developments this period reinforced the value of therapeutic mechanisms that can extend beyond their initial disease setting.
Tezepelumab met both co-primary endpoints and all key secondary endpoints in the Phase III CROSSING trial in eosinophilic esophagitis, with improvements maintained through week 52. The result extends the clinical relevance of TSLP inhibition into another epithelial-driven inflammatory disease after established use in severe asthma and chronic rhinosinusitis with nasal polyps.
Satralizumab is following a similar expansion path. The FDA granted Priority Review in MOGAD based on Phase III METEOROID results showing a 68% reduction in relapse risk versus placebo, while the EMA validated the European application. Earlier in development, Teva reported that a single dose of the anti-IL-15 antibody TEV ’408 significantly reduced gluten-induced intestinal damage in a Phase IIa celiac disease study, adding another potential indication alongside its vitiligo program.
The market implication is that a validated mechanism can create more value when it supports multiple clinically distinct franchises. Successful expansion can broaden the addressable population, increase returns on accumulated development knowledge and give companies more options for lifecycle management.
The key uncertainty is differentiation. Positive biology across several diseases does not guarantee competitive strength in each indication. Full datasets, regulatory outcomes and performance against evolving standards of care will determine how much value these expansions ultimately create.
Autoimmune CAR-T Safety Challenges Put Manufacturing and Patient Selection Under Scrutiny
Autoimmune CAR-T experienced the most significant development setback of the reporting period.
Novartis temporarily halted multiple studies of rap-cel across systemic lupus erythematosus, systemic sclerosis, vasculitis, inflammatory myopathies and neurological autoimmune diseases after three serious IEC-HS events resulted in deaths. Bristol Myers Squibb also paused enrollment across its zola-cel autoimmune program after inflammatory events that the company described as transient and reversible.
These developments matter because autoimmune CAR-T is being explored as a way to achieve deeper immune reset in patients with severe disease. However, the acceptable risk profile in chronic autoimmune conditions may differ substantially from oncology, particularly where biologic and oral treatment options already exist.
Both programs use rapid manufacturing approaches, creating additional interest in whether cellular expansion or manufacturing characteristics could contribute to toxicity. Analysts cited in the source material raised this possibility, but no causal relationship has been established.
For the market, safety may become a core source of differentiation alongside depth and durability of response. Manufacturing design, cellular kinetics, conditioning approaches and patient selection could therefore shape competitive positioning as much as efficacy.
The key uncertainty is whether these events reflect issues specific to individual programs or a broader challenge for rapidly manufactured autologous CAR-T in autoimmune disease. Safety reviews and decisions on restarting enrollment will be important indicators.
Durable Disease Control Is Becoming a Stronger Differentiator in Chronic Immunology
Longer-term evidence also featured prominently during the period, reinforcing the importance of sustained disease control in chronic immunology markets.
Bristol Myers Squibb reported two-year POETYK PsA-2 extension data showing maintained clinical responses with deucravacitinib through week 104, with no new safety signals. The results add longer-term support following approval in active psoriatic arthritis earlier in 2026.
Roche’s MOGAD filing is similarly built around prevention of future disease activity rather than short-term symptomatic improvement. In METEOROID, 87% of patients receiving satralizumab remained relapse-free at 48 weeks compared with 67% on placebo. Tezepelumab’s CROSSING results also showed disease and symptom improvements sustained through week 52.
This matters commercially as well as clinically. In chronic diseases, durable efficacy and consistent safety can influence physician confidence, treatment persistence and positioning within increasingly crowded treatment pathways. Evidence that a therapy continues to control disease beyond the initial trial period can therefore strengthen differentiation even when several options achieve meaningful short-term responses.
The key uncertainty is how controlled-trial durability translates into real-world treatment persistence, sequencing and adoption. Comparative evidence and longer follow-up will become more important as therapeutic choice expands.
AI and Multimodal Data Move Deeper Into Immunology Drug Discovery
The reporting period also showed AI partnerships becoming more closely integrated with pharmaceutical discovery workflows.
Owkin expanded its relationship with Boehringer Ingelheim through a license covering its K Pro AI Scientist platform and multimodal patient data in oncology and immunology. The agreement builds on an earlier pilot and includes the generation of new multimodal immunology datasets.
AbbVie separately entered a multi-year collaboration with Iambic to apply AI-enabled molecular design across immunology, neuroscience and oncology. The partnership is intended to support both first-in-class and best-in-class small-molecule programs.
These agreements indicate a shift from isolated computational projects toward platforms combining proprietary datasets, predictive models and pharmaceutical discovery expertise. That may be particularly relevant in immunology, where heterogeneous patient populations and complex disease biology can make target selection and molecule optimization difficult.
The market implication is not that AI itself creates differentiation, but that better integration of data and computational tools could improve the quality and speed of R&D decisions.
The key uncertainty is translation. The value of these partnerships will ultimately depend on whether they generate differentiated candidates, improve development choices or produce measurable gains in research productivity.
Next Immunology Strategic Watchpoints
- Tezepelumab in eosinophilic esophagitis: Full CROSSING results and regulatory plans should clarify the strength of the efficacy profile and its potential positioning within EoE treatment.
- Autoimmune CAR-T safety reviews: Findings from the rap-cel and zola-cel pauses may provide important evidence on manufacturing, cellular kinetics and the feasibility of risk mitigation in autoimmune populations.
- Satralizumab in MOGAD: The FDA decision expected by 10 January 2027 could establish the first approved disease-modifying therapy for the indication.
- TEV ’408 across multiple diseases: Additional celiac disease analyses and progress in other indications will test whether IL-15 inhibition can support a broader multi-indication development strategy.
- AI-enabled discovery partnerships: Progress from the Owkin–Boehringer and AbbVie–Iambic collaborations will be worth tracking for evidence that platform capabilities translate into tangible drug-development programs.
Immunology Strategic Roundup: Key Takeaway
Immunology entered this period with two competing strategic signals: validated mechanisms are creating credible opportunities for expansion across diseases, while more complex modalities are being forced to prove that their potential efficacy can be delivered within an acceptable safety framework. Longer-term evidence is also becoming more important to differentiation, particularly in chronic disease markets where durability can influence treatment choice and persistence. At the same time, investment in AI and multimodal data is shifting part of the competitive contest upstream. The emerging advantage may therefore lie in combining portable biology with durable evidence, manageable risk and more productive discovery infrastructure.
🌐 Explore LucidQuest Strategic Roundups across multiple therapy areas for deeper healthcare and pharma analysis
About LucidQuest
LucidQuest helps organizations anticipate change by identifying emerging signals, market shifts, and strategic opportunities.
Learn more: www.lqventures.com
Contact us at: info@lqventures.com